These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Standard therapies versus novel therapies in Hodgkin lymphoma. Gallamini A; Di Raimondo F; La Nasa G; Romano A; Borra A; Greco M Immunol Lett; 2013; 155(1-2):56-9. PubMed ID: 24140162 [TBL] [Abstract][Full Text] [Related]
5. SOHO State of the Art Updates and Next Questions | From Biology to Therapy: Progress in Hodgkin Lymphoma. Chohan KL; Ansell SM Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):705-713. PubMed ID: 37344332 [TBL] [Abstract][Full Text] [Related]
6. [Brentuximab vedotin and immune checkpoint inhibitors for the treatment of Hodgkin lymphoma]. Maruyama D Rinsho Ketsueki; 2020; 61(8):890-900. PubMed ID: 32908053 [TBL] [Abstract][Full Text] [Related]
7. [Current Standards in the Treatment of Hodgkin Lymphoma]. Hellmuth JC Dtsch Med Wochenschr; 2024 Jun; 149(12):702-708. PubMed ID: 38781993 [TBL] [Abstract][Full Text] [Related]
8. An evaluation of brentuximab vedotin as a treatment option for stage III/IV Hodgkin lymphoma. Choi Y; Diefenbach CS Expert Rev Hematol; 2019 Oct; 12(10):801-808. PubMed ID: 31432732 [No Abstract] [Full Text] [Related]
9. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation. Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998 [TBL] [Abstract][Full Text] [Related]
10. Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin's lymphoma: a phase II, non-randomized controlled trial. Hochberg J; Basso J; Shi Q; Klejmont L; Flower A; Bortfeld K; Harrison L; van de Ven C; Moorthy C; Islam H; Gerard P; Voss S; Cairo MS J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35584865 [TBL] [Abstract][Full Text] [Related]
11. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial. Cheson BD; Bartlett NL; LaPlant B; Lee HJ; Advani RJ; Christian B; Diefenbach CS; Feldman TA; Ansell SM Lancet Haematol; 2020 Nov; 7(11):e808-e815. PubMed ID: 33010817 [TBL] [Abstract][Full Text] [Related]
12. Inhibitors of ADAM10 reduce Hodgkin lymphoma cell growth in 3D microenvironments and enhance brentuximab-vedotin effect. Pece R; Tavella S; Costa D; Varesano S; Camodeca C; Cuffaro D; Nuti E; Rossello A; Alfano M; D'Arrigo C; Galante D; Ravetti JL; Gobbi M; Tosetti F; Poggi A; Zocchi MR Haematologica; 2022 Apr; 107(4):909-920. PubMed ID: 34109776 [TBL] [Abstract][Full Text] [Related]
13. Controversies in the Approach to Initial Therapy of Hodgkin Lymphoma. Allen PB; Winter JN Curr Oncol Rep; 2019 Mar; 21(5):39. PubMed ID: 30919161 [TBL] [Abstract][Full Text] [Related]
14. Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition? Othman T; Herrera A; Mei M Curr Hematol Malig Rep; 2021 Feb; 16(1):1-7. PubMed ID: 33409966 [TBL] [Abstract][Full Text] [Related]
15. Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin's lymphoma. Ju W; Zhang M; Wilson KM; Petrus MN; Bamford RN; Zhang X; Guha R; Ferrer M; Thomas CJ; Waldmann TA Proc Natl Acad Sci U S A; 2016 Feb; 113(6):1624-9. PubMed ID: 26811457 [TBL] [Abstract][Full Text] [Related]
17. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. Diefenbach CS; Hong F; Ambinder RF; Cohen JB; Robertson MJ; David KA; Advani RH; Fenske TS; Barta SK; Palmisiano ND; Svoboda J; Morgan DS; Karmali R; Sharon E; Streicher H; Kahl BS; Ansell SM Lancet Haematol; 2020 Sep; 7(9):e660-e670. PubMed ID: 32853585 [TBL] [Abstract][Full Text] [Related]
18. [Toxicity of targeted therapies and immunotherapy with checkpointinhibitors in Hodgkin lymphoma]. Michot JM; Lazarovici J Rev Prat; 2023 Jun; 73(6):641-650. PubMed ID: 37458554 [TBL] [Abstract][Full Text] [Related]
19. A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma. Oak E; Bartlett NL Expert Opin Drug Saf; 2016 Jun; 15(6):875-82. PubMed ID: 27139729 [TBL] [Abstract][Full Text] [Related]
20. Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapy. Moskowitz AJ Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):207-212. PubMed ID: 30504312 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]